Skip to main content

View full-text article in PMC

. 2011 Oct 14;17(38):4289–4297. doi: 10.3748/wjg.v17.i38.4289

Table 4.

Caspase-3 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	12.32 ± 0.8^e ^a	11.21 ± 1.05^e ^a	8.86 ± 1.01^e ^a
rAd-p53	5 × 10⁶	0	7.89 ± 1.13^c ^a	6.07 ± 0.97^c ^a	4.32 ± 1.03^c ^a
	5 × 10⁷	0	10.03 ± 1.03^c ^a	8.38 ± 1.04^c ^a	6.03 ± 0.99^c ^a
	5 × 10⁸	0	12.34 ± 1.05^c ^a	10.52 ± 0.89^c ^a	8.31 ± 1.02^c ^a
	5 × 10⁹	0	15.04 ± 1.03^c ^a	11.34 ± 0.55^c ^a	10.12 ± 1.01^c ^a
rAd-p53 + OXA	5 × 10⁶	3.2	22.05 ± 1.01^e ^c ^a	15.67 ± 1.03^e ^c ^a	13.48 ± 1.01^e ^c ^a
	5 × 10⁷	3.2	25.13 ± 1.06^e ^c ^a	18.83 ± 1.02^e ^c ^a	15.32 ± 1.07^e ^c ^a
	5 × 10⁸	3.2	27.24 ± 1.73^e ^c ^a	21.07 ± 1.01^e ^c ^a	18.93 ± 1.06^e ^c ^a
	5 × 10⁹	3.2	35.67 ± 1.03^e ^c ^a	26.16 ± 1.05^e ^c ^a	22.34 ± 1.13^e ^c ^a
Control	0	0	1.32 ± 1.02	1.29 ± 0.97	1.27 ± 0.68

^a

P < 0.05 vs control;

^c

P < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^e

P < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.